Melinta Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MELINTA THERAP, and when can generic versions of MELINTA THERAP drugs launch?
MELINTA THERAP has two approved drugs.
There are three US patents protecting MELINTA THERAP drugs.
There are thirty-seven patent family members on MELINTA THERAP drugs in seventeen countries and ten supplementary protection certificates in ten countries.
Drugs and US Patents for Melinta Therap
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 9,682,061 | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 8,420,592 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Melinta Therap
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,840,684 | ⤷ Sign Up |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,998,581 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Melinta Therap Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 2337575 | ⤷ Sign Up |
European Patent Office | 3169345 | ⤷ Sign Up |
Japan | 2012501349 | ⤷ Sign Up |
New Zealand | 591525 | ⤷ Sign Up |
Poland | 2337575 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Melinta Therap Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2337575 | SPC/GB16/054 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY ORITAVANCIN DIPHOSPHATE.; REGISTERED: UK EU/1/15/989/001 20150323 |
2337575 | 2016019 | Norway | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415 |
2337575 | 122016000075 | Germany | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
2337575 | 16C0039 | France | ⤷ Sign Up | PRODUCT NAME: ORITAVANCINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,TELS QUE LES SELS DIPHOSPHATES; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
2337575 | 1690041-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.